Four years into Donald Trump’s unpredictable Presidency, one constant theme has been headlines about executive action on drug pricing.
From his pre-Inauguration Day declaration that the industry is “getting away with murder,” through the 2018 Rose Garden unveiling of the HHS “Blueprint” and right up through the signing of four (or maybe only three) Executive Orders last month, headlines promising action on drug prices have been a regular feature of the Trump era